skip to content

Interim Results

Abbott Laboratories sales up

22 July 2015 13:11

Abbott Laboratories' second-quarter worldwide sales of $5.2bn increased 10.8% on an operational basis and 2.2% on a reported basis.

Worldwide sales increased 6.4 percent excluding the impact of 2014 acquisitions and foreign exchange.

Diluted EPS from continuing operations on both an adjusted and GAAP basis was $0.52 in the second quarter.

Abbott's full-year 2015 adjusted EPS guidance range for continuing operations remains unchanged at $2.10 to $2.20.

Projected full-year 2015 EPS for continuing operations under GAAP is $1.50 to $1.60.

Chairman and chief executive Miles D. White said: "We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses.

"We're well on track to achieve our financial objectives for the year despite a challenging currency environment."

Story provided by

Related Company: ABT

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.